GSK’s RSV vaccine wins European approval
LONDON — The European Commission approved GSK’s RSV vaccine, the company said Wednesday, bringing to the market the first such tool that can protect older adults from the common respiratory bug.
The vaccine, Arexvy, was authorized for adults 60 and older. Arexvy won U.S. regulatory licensure last month, as did another RSV immunization, Pfizer’s Abrysvo. The European Medicines Agency is reviewing Pfizer’s vaccine.
Read Original Article: GSK’s RSV vaccine wins European approval »
